alexa Variable Market Exclusivity Periods for Pharmaceuticals
ISSN: 2471-268X

Health Economics & Outcome Research: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Perspective Article

Variable Market Exclusivity Periods for Pharmaceuticals

Michael Hsu1, Ali Thaver2 and Gerard Anderson3*

1Johns Hopkins School of Medicine, Baltimore, Maryland, USA

2Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA

3Department of Health Policy and Management, Bloomberg School of Public Health, Baltimore, Maryland, USA

*Corresponding Author:
Gerard Anderson
Department of Health Policy and Management
Bloomberg School of Public Health
Baltimore, Maryland, USA
Tel: 410-955-3241
E-mail: [email protected]

Received date: March 04, 2016; Accepted date: March 15, 2016; Published date: March 22, 2016

Citation: Hsu M, Thaver A, Anderson G (2016) Variable Market Exclusivity Periods for Pharmaceuticals. Health Econ Outcome Res Open Access 2:111.

Copyright: © 2016 Hsu M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Pharmaceutical companies are given a market exclusivity period that does not vary based on the level of research and development (R&D) or the profits earned. The main purpose of this period is to protect the intellectual capital invested in a product allowing the inventor sufficient time to recoup the R&D costs and to be able to earn a profit. Currently, only 2 in 10 marketed drugs are profitable and drug companies earn substantial profits on only a few blockbuster drugs. As a result, there are many neglected diseases and drug companies charge very high prices for these few profitable drugs. These high prices can restrict access; for example, less than 10% of people with hepatitis C receive the appropriate drug primarily because of its high cost. A variable length market exclusivity period that takes into account a drug’s R&D cost (including the cost of all related products) and profits would provide greater incentives to invest in total R&D, R&D for a wider range of diseases and result in lower prices for expensive specialty drugs leading to greater access.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords